Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
On July 14, 2014, the Administrators notified the Company of increases in notional interests in Ordinary Shares for several individuals following the re-investment of the dividend paid on July 10, 2014. The transaction price was 1567.25 pence per Share. Specific increases included:
- Ms E Walmsley: 763.922 shares
- Mr S A Hussain and Dr P J T Vallance: 416.708 shares each
- Mr R G Connor, Mr D S Redfern, and Ms C Thomas: 333.367 shares each
- Mrs V A Whyte: 184.180 shares
- Mr J Ford: 49.409 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the dividend payment date of July 10, 2014, and the corresponding reinvestment price of 1567.25 pence per share.
- Confirm the specific share counts for each named director and executive in the Deferred Investment Award Programme.
- Review the full list of directors and persons discharging managerial responsibility to ensure all required notifications were filed.